Blog
Building a culture of well-being: Employee mental health support
Prefilled syringes (PFS) are innovative drug delivery systems that are increasingly being adopted in the healthcare industry, especially for clinical trials and chronic disease therapy. The global PFS market is projected to reach $13.33 billion by 2028, with a compound annual growth rate (CAGR) of 11.11%. But non-adherence and compliance errors can be issues when administering therapies via a PFS. One solution is a connected, sensor-enabled PFS that can automatically keep a record of injections and more effectively monitor treatment compliance and adherence.
Flex has developed several smart PFS solutions to address customer requirements and usability scenarios. In the March 2024 issue of Drug Development and Delivery, Flex Innovation Manager Salvatore Forte details Flex’s concepts for a connected PFS that can be turned quickly into end products to advance clinical trial outcomes and equip healthcare providers with reliable data. This includes the meaningful criteria used to result in a full-featured device, such as security, sustainability, and the analysis of associated cost.
